Shots:
- Aytu has collaborated with Fabre-Kramer to commercialize Exxua in the US for treating major depressive disorder; launch is expected in Q4’25
- As per the deal, Fabre-Kramer has received $3M upfront & is eligible to receive $3M within 45 days of the Exxua’s 1yr. commercial sale, increasing to $5M if net sales reach $35M as well as milestones ranging from $5M to $100M/yr. after $100M of sales, with 10% on sales beyond $1B; Company will also receive a 3% supply price, increasing to 4% if net sales exceed $300M
- Fabre will obtain royalties starting at 28% of net sales, increasing to 39% if annual sales exceed $300M, & after a royalty reduction trigger is met, rates adjust to 24.5%, increasing to 35.5% if sales again exceed $300M
Ref: AccessNewswire | Image: Aytu BioPharma and Fabre-Kramer Pharmaceuticals| Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
